Disease-specific amino acid infusion (F080) in hepatic encephalopathy

A prospective, randomized, double-blind, controlled trial

F. B. Cerra, N. K. Cheung, J. E. Fischer, N. Kaplowitz, E. R. Schiff, J. L. Dienstag, R. H. Bower, C. D. Mabry, C. M. Leevy, Thomas W Kiernan

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Seventy-five patients with acute hepatic decompensation superimposed on chronic alcoholic cirrhosis were prospectively randomized for a blinded trial of the treatment of hepatic encephalopathy. The control group received 4 g of enteral neomycin daily along with 25% dextrose by a central venous catheter. The experimental group received a placebo resembling neomycin and isocaloric dextrose plus a modified amino acid mixture enriched with branched-chain amino acids to 36% and deficient in aromatic amino acids and methionine. Thirty patients in the F080 group and 29 in the control group completed the trial. The group receiving the modified amino acid mixture demonstrated a statistically significant improvement in encephalopathy as compared to the neomycin group, while maintaining nitrogen equilibrium. Survival and discharge from the hospital were statistically greater in the group treated with the modified amino acid solution and hypertonic dextrose. Treatment of hepatic encephalopathy in the presence of hepatic decompensation with an amino acid solution formulated for its treatment seems to produce faster, more complete recovery with improved capacity for nutritional support.

Original languageEnglish (US)
Pages (from-to)288-295
Number of pages8
JournalJournal of Parenteral and Enteral Nutrition
Volume9
Issue number3
DOIs
StatePublished - Jan 1 1985
Externally publishedYes

Fingerprint

Hepatic Encephalopathy
Neomycin
Amino Acids
Glucose
Hypertonic Solutions
Alcoholic Liver Cirrhosis
Branched Chain Amino Acids
Aromatic Amino Acids
Control Groups
Nutritional Support
Central Venous Catheters
Liver
Brain Diseases
Methionine
Small Intestine
Nitrogen
Therapeutics
Placebos
Survival

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Disease-specific amino acid infusion (F080) in hepatic encephalopathy : A prospective, randomized, double-blind, controlled trial. / Cerra, F. B.; Cheung, N. K.; Fischer, J. E.; Kaplowitz, N.; Schiff, E. R.; Dienstag, J. L.; Bower, R. H.; Mabry, C. D.; Leevy, C. M.; Kiernan, Thomas W.

In: Journal of Parenteral and Enteral Nutrition, Vol. 9, No. 3, 01.01.1985, p. 288-295.

Research output: Contribution to journalArticle

Cerra, F. B. ; Cheung, N. K. ; Fischer, J. E. ; Kaplowitz, N. ; Schiff, E. R. ; Dienstag, J. L. ; Bower, R. H. ; Mabry, C. D. ; Leevy, C. M. ; Kiernan, Thomas W. / Disease-specific amino acid infusion (F080) in hepatic encephalopathy : A prospective, randomized, double-blind, controlled trial. In: Journal of Parenteral and Enteral Nutrition. 1985 ; Vol. 9, No. 3. pp. 288-295.
@article{16a41f0ab2a248678a5a46fca1655b30,
title = "Disease-specific amino acid infusion (F080) in hepatic encephalopathy: A prospective, randomized, double-blind, controlled trial",
abstract = "Seventy-five patients with acute hepatic decompensation superimposed on chronic alcoholic cirrhosis were prospectively randomized for a blinded trial of the treatment of hepatic encephalopathy. The control group received 4 g of enteral neomycin daily along with 25{\%} dextrose by a central venous catheter. The experimental group received a placebo resembling neomycin and isocaloric dextrose plus a modified amino acid mixture enriched with branched-chain amino acids to 36{\%} and deficient in aromatic amino acids and methionine. Thirty patients in the F080 group and 29 in the control group completed the trial. The group receiving the modified amino acid mixture demonstrated a statistically significant improvement in encephalopathy as compared to the neomycin group, while maintaining nitrogen equilibrium. Survival and discharge from the hospital were statistically greater in the group treated with the modified amino acid solution and hypertonic dextrose. Treatment of hepatic encephalopathy in the presence of hepatic decompensation with an amino acid solution formulated for its treatment seems to produce faster, more complete recovery with improved capacity for nutritional support.",
author = "Cerra, {F. B.} and Cheung, {N. K.} and Fischer, {J. E.} and N. Kaplowitz and Schiff, {E. R.} and Dienstag, {J. L.} and Bower, {R. H.} and Mabry, {C. D.} and Leevy, {C. M.} and Kiernan, {Thomas W}",
year = "1985",
month = "1",
day = "1",
doi = "10.1177/0148607185009003288",
language = "English (US)",
volume = "9",
pages = "288--295",
journal = "Industrial Laboratory (USSR) (English translation of Zavodskaya Laboratoriya)",
issn = "0019-8447",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Disease-specific amino acid infusion (F080) in hepatic encephalopathy

T2 - A prospective, randomized, double-blind, controlled trial

AU - Cerra, F. B.

AU - Cheung, N. K.

AU - Fischer, J. E.

AU - Kaplowitz, N.

AU - Schiff, E. R.

AU - Dienstag, J. L.

AU - Bower, R. H.

AU - Mabry, C. D.

AU - Leevy, C. M.

AU - Kiernan, Thomas W

PY - 1985/1/1

Y1 - 1985/1/1

N2 - Seventy-five patients with acute hepatic decompensation superimposed on chronic alcoholic cirrhosis were prospectively randomized for a blinded trial of the treatment of hepatic encephalopathy. The control group received 4 g of enteral neomycin daily along with 25% dextrose by a central venous catheter. The experimental group received a placebo resembling neomycin and isocaloric dextrose plus a modified amino acid mixture enriched with branched-chain amino acids to 36% and deficient in aromatic amino acids and methionine. Thirty patients in the F080 group and 29 in the control group completed the trial. The group receiving the modified amino acid mixture demonstrated a statistically significant improvement in encephalopathy as compared to the neomycin group, while maintaining nitrogen equilibrium. Survival and discharge from the hospital were statistically greater in the group treated with the modified amino acid solution and hypertonic dextrose. Treatment of hepatic encephalopathy in the presence of hepatic decompensation with an amino acid solution formulated for its treatment seems to produce faster, more complete recovery with improved capacity for nutritional support.

AB - Seventy-five patients with acute hepatic decompensation superimposed on chronic alcoholic cirrhosis were prospectively randomized for a blinded trial of the treatment of hepatic encephalopathy. The control group received 4 g of enteral neomycin daily along with 25% dextrose by a central venous catheter. The experimental group received a placebo resembling neomycin and isocaloric dextrose plus a modified amino acid mixture enriched with branched-chain amino acids to 36% and deficient in aromatic amino acids and methionine. Thirty patients in the F080 group and 29 in the control group completed the trial. The group receiving the modified amino acid mixture demonstrated a statistically significant improvement in encephalopathy as compared to the neomycin group, while maintaining nitrogen equilibrium. Survival and discharge from the hospital were statistically greater in the group treated with the modified amino acid solution and hypertonic dextrose. Treatment of hepatic encephalopathy in the presence of hepatic decompensation with an amino acid solution formulated for its treatment seems to produce faster, more complete recovery with improved capacity for nutritional support.

UR - http://www.scopus.com/inward/record.url?scp=0021886153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021886153&partnerID=8YFLogxK

U2 - 10.1177/0148607185009003288

DO - 10.1177/0148607185009003288

M3 - Article

VL - 9

SP - 288

EP - 295

JO - Industrial Laboratory (USSR) (English translation of Zavodskaya Laboratoriya)

JF - Industrial Laboratory (USSR) (English translation of Zavodskaya Laboratoriya)

SN - 0019-8447

IS - 3

ER -